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INTRODUCTION
The treatment of subclinical human papillomavirus (HPV) 1 infection is a matter of controversy. As defined by Reid et al (1982) , in this kind of HPV infection, instead of producing an overt condyloma, a "macroscopic invisible, non-papilliferous epithelial hyperplasia" can be produced. Considering the high incidence of cervical cancer worldwide, it would be reasonable to try to treat all forms of HPV infection to prevent future cancer development. However, considering the high frequency of spontaneous regression of HPV infection and the lack of a specific antiviral drug, many experts follow these patients conservatively and treat cervical intraepithelial neoplasia (CIN), should it develop.
The goal of this paper is to search for evidence of efficacy of any treatment for subclinical HPV infection of the cervix when there is no concomitant CIN using a systematic review of the medical literature.
METHODS

Study search
A comprehensive search in the medical literature was performed, including both published and unpublished studies. Studies were identified using reference databases (Medline, Compact Medical Librarian-AIDSLINE, LILACS, Excerpta Medica, Popline and the Cochrane Library), other authors' reference lists, abstracts of studies presented in meetings related to cervical pathology, information from experts that work in the area, information from institutions that financially support clinical research, Clinical Tri-als Registries, government agencies, pharmaceutical companies and Internet sites.
In digital media, the search was carried out using terms related to uterine cervix, treatment and subclinical HPV infection (Table 1) . The search period ranged from 1977 to March 1997, since the first studies linking HPV to cervical neoplasia date from 1977. Studies published in English, Spanish or Portuguese were included.
The studies identified were obtained and their methodology was assessed to verify their internal validity.
The criteria used to diagnose HPV infection varied between authors. Different diagnostic criteria were accepted if they were used consistently within a given study, i.e. used to both select patients and to determine outcome. This allowed us to include studies done prior to the availability of HPV-DNA detection methods and to avoid selection bias.
HPV infection diagnostic criteria included cytology, colposcopy, histology or a combination of these methods. Some of the more recent studies also used HPV-DNA detection methods in their analysis.
An instrument was built to assess the internal validity of each study and identify studies for selection, based on criteria adapted from Guyatt et al [2] [3] [4] (Table 2) . We assessed the reliability of this instrument between two of the present authors (FR & SCF), assessing the internal validity of a sample of 15% of the studies identified, and concluding that it had good reliability. [5] [6] [7] [8] Each study was masked, with only its methodology section being assessable. Studies that met inclusion criteria had their data extracted, including sample size, treatment tested and treatment outcome in the experimental and control groups. Data was analyzed and synthesized but could not be combined because of differences in treatment modalities.
RESULTS
Results of the study search
Studies identified are listed in the Reference section (references 9 through 75) and a summary of the results of the study search from each source is shown in Table 3 . Eight studies could not be obtained for review (references 9 through 16). 
GENERAL ASPECTS
• Study of treatment for subclinical HPV infection of the cervix without intraepithelial neoplasia (studies using the term "low grade lesion" published after 1990, were also considered).
• Complete investigation, with final results shown.
METHODOLOGICAL ASPECTS
• Randomized clinical trial, placebo-controlled.
• Identical and valid diagnostic methods used to identify infected women and to measure the results after intervention.
• Loss to follow-up of 10% or less.
• Follow-up period of at least one month.
• Intention-to-treat analysis.
• Experimental and control groups similar at entry into the study concerning age and other factors that could interact with any treatment modality. Differences need to have been checked prior to analysis.
• The groups must be treated and followed equally, apart from the experimental intervention. 
Study selection
Of the 59 studies obtained in their full version, 5 were included [19] [20] [21] [22] [23] and 54 were excluded. 17, 18, The primary reason why studies were excluded was their study design (42 studies -77%). The remaining 12 (22%) showed one of the following situations: four were clinical trials but were not placebo-controlled; two had more than 10% of patients lost to follow-up; one tested adjuvant therapy instead of primary therapy; one assessed the outcome differently in experimental and control groups; one analyzed patients with HPV without CIN together with patients with CIN I (published before 1990) or CIN II; one tested the therapy on clinically-expressed HPV infection; one reported only preliminary data; and in one we were not able to extract the information needed from it.
In Table 4 and in the following text we show a brief summary of the five studies that met the inclusion criteria. Two studies included at first were then excluded. The first one was the study by Yliskoski et al, 1991. 17 They had studied a group of patients with HPV without CIN together with others with CIN. We wrote to one of the authors (KS) and he told us that the data was not available anymore. The other study was the one from Woodman et al, 1993 . 18 This study presents treatment outcomes from patients with progression risk and it was not stated how many patients had regression or progression. We wrote to the first author but we have not had any reply yet.
Boothby et al., 19 1990. This is a randomized clinical trial testing trichloroacetic acid (TCA) at 50% concentration, applied to the cervix. Thirty-four women with biopsy-proven HPV infection of the cervix were randomly allocated to receive TCA or normal saline in a blinded fashion. The outcome was assessed 16 weeks after treatment. The treatment was considered a failure if there was evidence of HPV on Pap smear or biopsy. The text does not provide a similarities analysis between the groups after treatment allocation. Although the authors state that patients and investigators were blinded to the treatment allocation, there is a marked difference in cervix appearance after applying the two substances. The application of TCA turns the cervix surface white, as a result of chemical coagulation of its epithelium proteins and impairment in viewing the color of the stroma. If this had been reported in patient records, to the patient or kept in mind by the medical doctor, the blinding could have been impaired (potential source of assessment bias). When the first 15 patients in each group were analyzed, no differences were noted and the study was closed. No patients were lost to follow-up. Six women in the experimental group and two in the control group had undesirable side effects. Two women in the experimental group developed CIN I.
Diakomanolis et al., 20 1990. This study enrolled 452 women with biopsyproven HPV cervical infection without CIN. The authors report that "patients were allocated randomly under a specific number" (page 506), which is unclear to us. There is no similarities analysis between the study groups after the allocation for treatment. The study group had vaporization of the entire transformation zone, distal endocervical canal and "brushing" of the cervix portio while the control group received no treatment. It was not possible to blind the procedure being studied to patients and investigators. After 18 months, 8 (5.6%) women from the treatment group and 24 (7.7%) of the control group showed progression to pre-invasive disease (P = 0.42). No data was presented on the disappearance of the disease.
Ruge et al., 21 1992. In this study 50 women with biopsy-proven HPV infection with or without concomitant CIN I were randomly allocated to a laser group or a control group. There is no information about the randomization method used. However, despite this limitation, there were no statistical differences between study and control groups in age, smoking, socioeconomic status, sexual habits and contraceptive methods. The treatment group had their entire transformation zone "evaporated" to a depth of 4-5 mm. The control group had no treatment. As in the previous study, there was no patient or *Other groups were selected, with CIN I to CIN III, but these data were not used in our review.
investigator blinding regarding which group each patient was allocated to. After 12 months, the authors analyzed regression, persistence and progression and found no statistical differences between the two groups.
Hording et al., 22 1993. In this study, the authors analyzed 46 women with biopsy-proven HPV cervical infection with or without CIN I. These women were allocated randomly to a treatment group (laser vaporization of the cervix) or to a control group without treatment. The authors did not report the randomization method used and there is no analysis of group similarities after treatment allocation. As in the two previous studies, there was no patient or investigator blinding concerning treatment or control procedures. No patients were lost to follow-up, with mean follow-up of 28 months (range of 12 to 54 months). There were no significant differences between the study groups.
Fairley et al., 23 1996. Considering epidemiological and laboratory evidence that beta carotene may be of value in the treatment of pre-invasive cervical disease, these authors performed a double-blind clinical trial in which 117 women were randomly allocated to receive beta carotene (30 mg/daily) or placebo (lecithin, 400 mg/daily) for one year. There is no report of the randomization method used but the groups were similar in age, marital status, smok- ing, contraceptive method, parity and number of sexual partners. After one year of follow-up no differences were found between the study groups in terms of lesion clearance. Thirteen per cent of the women receiving betacarotene noticed yellowing of the skin. Table 5 shows data extracted from the selected studies concerning progression of HPV infection without CIN to presence of CIN or from HPV with CIN I to higher grades of CIN. Table 6 shows data related to disappearance of subclinical HPV with or without CIN I.
Information extracted from the selected studies
Three studies included an analysis of the presence of HPV-DNA and its disappearance after the experimental period. These data are shown in Table 7 .
DISCUSSION
From the 59 studies identified, obtained and reviewed, only five met the inclusion criteria. None of these found any difference between treatment and control groups in either progression or regression of subclinical HPV infection of the cervix. However, these studies were limited by one or more problems, such as the sample size, difficulties in blinding patients and investigators, and we do not know the randomization method used by four of them. These limitations leave us unsure that the treatments tested are ineffective.
Most studies identified were excluded because of lack of internal validity for adequately testing any form of treatment. Although we could not obtain 8 studies in their full version, even after attempts using national or foreign libraries and asking the authors for them (in the case of studies identified in Books of Abstracts from medical meetings), assessment of their abstracts allowed us to conclude that they would probably be excluded because they were not clinical trials.
In the decision-making process concerning the use of any therapy to treat this kind of HPV infection, we must consider the lack of evidence that treatment is better than no treatment. The use of therapies in which efficacy is not proven can lead to unnecessary waste of money or can be worse than the illness itself, considering the physical consequences of some of them and the psychological consequences of trying to treat an infection that can present recurrence.
Well-conducted randomized clinical trials can be expected to prove some therapy to be effective against subclinical HPV infection, preferably with patient and investigators being blinded, and with sufficient sample size with enough power to avoid beta error (i.e. saying that there is no difference between treatment and no treatment when it actually exists and the only reason that statistical significance was not achieved was because of the small sample size).
However, applying financial resources to conduct an experiment to clarify this question appear unreasonable to us. Given the high prevalence reported by some authors, varying between 13 to 20% in developing countries, in which Brazil is included, 76 and the transient characteristic of most of these infections, 77 the cost of medicine usage, therapeutic procedures or vaccines would not be reasonable in the prevention of cervical cancer.
On the other hand, there is already strong evidence of efficacy in treatment of pre-invasive diseases in order to prevent cervical cancer. It seems to us that it is more cost-effective to apply these procedures to the patients that present CIN II/III, considering that they are a small proportion of all HPV-infected women.
CONCLUSIONS
The evidence we found for efficacy in treatment of subclinical HPV infection of the cervix without CIN was unsatisfactory. However, considering the limitations of the selected studies, particularly in terms of sample size, possible efficacy in these treatments cannot be excluded.
In many of the studies excluded for methodological reasons, the authors' conclusion was clearly in favor of the treatments tested, possibly leading to ineffective or even potentially harmful therapies and to unnecessary costs.
Medline, LILACS and Excerpta Medica were the most useful sources of references, and identified all of the studies included.
